GVB Biopharma Goes Private Again

GVB Biopharma, a pioneer in the hemp and cannabis industry, has transitioned back to a private company controlled by its founding team.

Acquired by 22nd Century Group in May 2022, this strategic move marks a new chapter in GVB's story.

As a privately held company, GVB Biopharma is positioned to leverage its industry-leading expertise in research, genetics, and proprietary technologies. This transition allows for a more agile approach in meeting the evolving needs of the global hemp and cannabis markets, while pursuing ambitious growth and excellence in serving its customers.

GVB Biopharma remains at the forefront of the industry with its cutting-edge cryogenic hemp extraction methods, refining, conversion, and advanced product formulation technologies. As a leading supplier of cannabinoids, GVB is committed to maintaining its reputation for high-quality, trusted products.

"As the hemp industry continues to mature, our vision and capabilities align perfectly with the market's direction," said Drew Spiegel, CEO of GVB Biopharma. "We are excited to lead the charge in this next phase of industry growth, driven by our commitment to quality, innovation, and our valued customers."

GVB was founded in the farm country of central Oregon in 2016 by three best friends who have known each other since high school.